Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
about
Inflammatory breast cancer: a model for investigating cluster-based dissemination.Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?New insights into the role of EMT in tumor immune escape.Immunoproteasomes and immunotherapy-a smoking gun for lung cancer?Deciphering Epithelial-Mesenchymal Transition Regulatory Networks in Cancer through Computational ApproachesAntigen processing and immune regulation in the response to tumours.Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases.Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems TheoryEpithelial-mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease.Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy.Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.The combination of checkpoint immunotherapy and targeted therapy in cancer.Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling.Transcription factor SPZ1 may promote TWIST-mediated epithelial-mesenchymal transition in thoracic malignancies.Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.Proteasome dysregulation in human cancer: implications for clinical therapies.MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination.Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.Analysis of Hierarchical Organization in Gene Expression Networks Reveals Underlying Principles of Collective Tumor Cell Dissemination and Metastatic Aggressiveness of Inflammatory Breast Cancer.Activation of viral defense signaling in cancerNext Generation Cancer Vaccines-Make It Personal!
P2860
Q33767606-3D0E5E88-71A4-46AF-8C96-945E9ED03777Q33869760-E6602FEB-27C2-4ADF-AFB0-7ACC08DB3B06Q33869781-4BEDFA83-5D02-4FD2-BC6C-34C0FBA3305DQ37121401-D9D88368-3720-4745-AF81-C33081795D66Q38616552-E606EB21-BD51-4565-879B-D6FBE9C113CBQ38818628-B06A350D-DE5E-4439-86F3-4843F6935B9DQ38838108-6FAA056F-6B09-46D1-AF9C-FCB95F392CB1Q39390852-7F51D09E-3820-4824-A1AB-B4FD7F275A0EQ39395614-0DE039A2-2FF6-42A7-B690-B2AF7CFA0C87Q41428789-5470D49E-9EE7-40C7-90E2-8F7288C89A67Q42336210-AF90B6C2-AEB1-4880-BC92-9E6DC11C7A5EQ45822425-6CFA9513-413B-47EE-B5BB-D242E1368676Q47098614-192A52BB-A704-46A2-BEF7-BD9C4147EBAAQ47100314-8CCDEEB4-2DDB-4DA1-AA34-01D3DCB185AEQ47162554-FD8F0D9F-1177-4484-BE67-BD15C9CF8767Q47165961-C4B82088-4D78-4A12-B8FF-4BB041BA5480Q47673602-40FB360D-8F75-4FFA-BC5A-7A7F07046629Q49501422-33E1C82E-62F3-49C2-81C4-088CC2A9F2A0Q50077966-B54680DC-D92D-4B2D-9685-36C74C52377CQ50926633-E1A41DB8-2A51-4997-95CE-D81804ABFF6DQ52317592-FCAB0CFA-77F0-4FDC-A222-ED29AB8ECCB4Q52606685-A62C5393-6AC1-45EF-BA0C-946F2CF26D9BQ55008935-9678626C-D6BD-42AF-A306-689CDF13C37EQ55691533-712C3B48-770E-4F46-B301-03A87FD83D62Q58695217-4FAB42F2-E4EB-4D6A-8CA2-06D0712D4FF8Q58791982-3DF534F7-13F2-4369-8F58-FDCBF8698756
P2860
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immunoproteasome deficiency is ...... ssociated with a poor outcome.
@ast
Immunoproteasome deficiency is ...... ssociated with a poor outcome.
@en
type
label
Immunoproteasome deficiency is ...... ssociated with a poor outcome.
@ast
Immunoproteasome deficiency is ...... ssociated with a poor outcome.
@en
prefLabel
Immunoproteasome deficiency is ...... ssociated with a poor outcome.
@ast
Immunoproteasome deficiency is ...... ssociated with a poor outcome.
@en
P2093
P2860
P50
P356
P1476
Immunoproteasome deficiency is ...... associated with a poor outcome
@en
P2093
Amin Momin
Carmen Behrens
Edwin J Ostrin
Eshel Ben-Jacob
Haley L Peters
Herbert Levine
Hiroyuki Katayama
Ignacio I Wistuba
P2860
P304
P356
10.1073/PNAS.1521812113
P407
P577
2016-02-29T00:00:00Z